NEW PRAGUE, Minn. / Aug 07, 2024 / Business Wire / Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that Jim Cunniff, President and Chief Executive Officer, and Brad Nagel, Chief Financial Officer, are scheduled to attend the Canaccord Genuity 44th Annual Global Growth Conference being held in Boston on August 13-15, 2024.
Electromed’s management team will present at 2:30 p.m. Eastern Time on Wednesday, August 14, 2024. A link to the live and archived webcast of the event will be available on the Electromed website under Events & Presentations. You can also access the live webcast here.
In advance of the event, Electromed has published an updated investor presentation deck for review by interested parties. The updated presentation can be found on the Electromed website at Events & Presentations or on the SEC website at www.sec.gov.
About Electromed, Inc.
Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota, and was founded in 1992. Further information about Electromed can be found at www.smartvest.com.
Last Trade: | US$29.79 |
Daily Change: | 1.72 6.13 |
Daily Volume: | 188,443 |
Market Cap: | US$250.240M |
November 12, 2024 October 28, 2024 August 27, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB